Biocartis Group NV: Biocartis announces publication of 2015 annual report and invitation to annual general meeting

Mechelen, Belgium, 12 April 2016 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces the publication of its 2015 annual report and the invitation for its annual general shareholders' meeting ('AGM').

The 2015 annual report provides an overview of the figures and performance of Biocartis for the financial year ended 31 December 2015 and can now be downloaded from the website of the Company (http://www.biocartis.com) as a PDF file.

Biocartis will hold its AGM on 13 May 2016 at 14:00 p.m. CEST (Central European Summer Time) and is delighted to invite its shareholders and warrant holders. A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available on the website of the Company (http://www.biocartis.com). The most important resolutions included in the agenda of the AGM relate to the annual accounts for the financial year ended on 31 December 2015 and the composition of the Board of Directors of the Company, including the appointment of Hilde Eylenbosch as a new independent director.

----- END ----

For more information:

Biocartis
Renate Degrave, Corporate Communications & Investor Relations
+32 15 632 600 | press@biocartis.com

About Biocartis 
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla(TM) addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has four oncology tests and one infectious disease test on the market. More information on: www.biocartis.com.